FHJ Scientific

FHJ Scientific is a biotechnology company specializing in the development of targeted alpha-particle therapies (TAT) for the treatment of various cancers. The company's core technology focuses on utilizing Lead-212 ($^{212}$Pb) as a therapeutic isotope, which is conjugated to specific targeting vectors like peptides to deliver high-energy radiation directly to tumor cells. Their lead programs include VMT01, targeting the melanocortin 1 receptor for metastatic melanoma, and VMT-α-NET, targeting somatostatin receptors for neuroendocrine tumors. Founded by researchers from the University of Iowa, the company provides a specialized platform for radiopharmaceutical discovery and development. In early 2023, FHJ Scientific was acquired by Perspective Therapeutics, which has since integrated FHJ's assets and expertise into its broader oncology pipeline.